Researchers aimed at identifying the factors that could predict the response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular (wet) age-related macular degeneration (nAMD). They performed this retrospective, post hoc analysis of VIEW 1/2. Patients were randomized 1:1:1:1 to 0.5 mg intravitreal aflibercept (IVT-AFL) injection every 4 weeks (0.5q4); 2 mg IVT-AFL every 4 weeks (2q4); 2 mg IVT-AFL every 8 weeks (2q8) after an initial three injections at weeks 0, 4 and 8 or 0.5 mg intravitreal ranibizumab every 4 weeks (0.5q4). They noted greater vision gains in association with younger age, lower visual acuity (VA) and smaller choroidal neovascularization (CNV) size at baseline over 52 weeks. While best-corrected VA 20/40 or better were more frequently observed in relation with younger age, higher VA and smaller CNV size at treatment start after a year’s treatment. This highlights early anti-VEGF treatment as beneficial for these patients.